Latest Headlines

Latest Headlines

Teva buy Mylan? It's not happening, BMO analyst says

Heard the Teva-Mylan takeover rumors? Forget them, one analyst says.

Mylan recalls drug after problem uncovered with Indian supplier

A problem with a supplier in India has led Mylan to voluntarily recall a cancer drug in Canada. The maker of generic drugs has recalled one lot of methotrexate injection after the discovery of particulate in a unit.

Should Teva buy Mylan? 'Close call,' analyst says

Rumors have been floating around for months that pickup-hungry Teva may be looking to buy generics competitor Mylan. Some analysts have dismissed the idea, pointing to reasons a buyout wouldn't work. But with the deal talk persisting, at least one analyst says the underlying logic for a tie-up is sound--as long as it doesn't happen right away.

To avoid becoming deal bait, Mylan CEO may have to make another big buy

It's been less than a week since Mylan completed its deal with Abbott, scooping up a large chunk of the Illinois company's overseas generics business. But CEO Heather Bresch is already hinting at another big transaction.

Mylan bags rights to distribute Gilead's Sovaldi in India

Gilead has named Mylan as the exclusive distributor of branded forms of its hepatitis C blockbusters Sovaldi and Harvoni in India.

Indian drugmakers line up to buy Ranbaxy drugs Sun must sell

At least 5 India drugmakers are reported to be interested in the 7 drugs Sun Pharmaceuticals has to sell before it can close its yearlong acquisition of Ranbaxy Laboratories.

FDA puts off Mylan's Nexium generic, giving Teva's version free rein

Good news for Teva when it comes to Mylan's generic version of AstraZeneca's Nexium: It won't be around for a little while.

FDA, Mylan issue reminder of voluntary recalls for antibiotic and antiseizure drugs

The FDA and Mylan have issued a reminder of the company's ongoing voluntary recalls for antibiotic and antiseizure drugs manufactured by Mylan's UDL Laboratories.

Mylan buys into Theravance's COPD contender in $265M deal

Generics giant Mylan is shouldering its way into the blockbuster market for COPD treatments, signing a $265 million deal with the respiratory experts at Theravance Biopharma to get its hands on a late-stage contender.

Sandoz recalls generic Atacand that Mylan manufactures in India

Novartis' generic division, Sandoz, is having to recall one lot of its generic version of Novartis' blood pressure drug Atacand, but it is a copy that it does not manufacture itself. The drug is made in India by Mylan.